دورية أكاديمية
Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.
| العنوان: | Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors. |
|---|---|
| المؤلفون: | Lo Presti S; Center for the Diagnosis and Treatment of Pericardial Diseases Section of Cardiovascular Imaging Department of Cardiovascular Medicine Heart, Vascular, and Thoracic InstituteCleveland Clinic Cleveland OH., Elajami TK; Columbia University Division of CardiologyMount Sinai Heart Institute Miami Beach FL., Reyaldeen R; Center for the Diagnosis and Treatment of Pericardial Diseases Section of Cardiovascular Imaging Department of Cardiovascular Medicine Heart, Vascular, and Thoracic InstituteCleveland Clinic Cleveland OH., Anthony C; Center for the Diagnosis and Treatment of Pericardial Diseases Section of Cardiovascular Imaging Department of Cardiovascular Medicine Heart, Vascular, and Thoracic InstituteCleveland Clinic Cleveland OH., Imazio M; University CardiologyA.O.U. Città della Salute e della Scienza di Torino Turin Italy., Klein AL; Center for the Diagnosis and Treatment of Pericardial Diseases Section of Cardiovascular Imaging Department of Cardiovascular Medicine Heart, Vascular, and Thoracic InstituteCleveland Clinic Cleveland OH. |
| المصدر: | Journal of the American Heart Association [J Am Heart Assoc] 2021 Oct 05; Vol. 10 (19), pp. e021685. Date of Electronic Publication: 2021 Sep 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Wiley-Blackwell |
| مواضيع طبية MeSH: | Neoplasms* , Pericarditis*/diagnosis , Pericarditis*/drug therapy, Humans ; Interleukin 1 Receptor Antagonist Protein ; Interleukin Inhibitors ; Interleukin-1 ; Quality of Life ; Recurrence |
| مستخلص: | Recurrent pericarditis (RP) is a complex inflammatory disorder associated with adverse outcomes and poor quality of life. After the first episode of acute pericarditis, a non-negligible group of patients will fail to achieve complete remission despite treatment and will be challenged by side effects from the chronic use of medications like corticosteroids. The cause of RP remains unknown in the majority of cases, mainly due to a gap in knowledge of its complex pathophysiology. Over the past 2 decades, the interleukin-1 (IL-1) pathway has been uncovered as a key element in the inflammatory cascade, allowing the development of pharmacological targets known as IL-1 inhibitors. This group of medications has emerged as a treatment option for patients with RP colchicine-resistance and steroid dependents. Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP. Although further studies are needed to refine therapeutic protocols and taper of concomitant therapies, IL-1 inhibitors, continue to consolidate as part of the pharmacological armamentarium to manage this complex condition with potential use as monotherapy. The aim of this review is to highlight the role of IL-1 pathway in RP and discuss the efficacy, safety, and clinical applicability of IL-1 inhibitors in the treatment of RP based on current evidence. |
| References: | J Am Heart Assoc. 2021 Aug 3;10(15):e018950. (PMID: 34284595) Ann Rheum Dis. 2014 Dec;73(12):2215-7. (PMID: 25165036) Circulation. 2013 Oct 22;128(17):1910-23. (PMID: 24146121) Heart. 2010 May;96(10):779-84. (PMID: 20448129) J Exp Med. 1972 Jul 1;136(1):128-42. (PMID: 5033417) Am Heart J. 2020 Oct;228:81-90. (PMID: 32866928) N Engl J Med. 2013 Oct 17;369(16):1522-8. (PMID: 23992557) Heart. 2008 Apr;94(4):498-501. (PMID: 17575329) Curr Opin Immunol. 2007 Dec;19(6):615-22. (PMID: 17977705) Lancet. 2014 Jun 28;383(9936):2232-7. (PMID: 24694983) Autoimmun Rev. 2012 Nov;12(1):60-5. (PMID: 22884556) J Am Coll Cardiol. 2016 Nov 29;68(21):2311-2328. (PMID: 27884251) Eur Heart J. 2015 Nov 7;36(42):2921-2964. (PMID: 26320112) Eur Heart J. 2005 Apr;26(7):723-7. (PMID: 15755753) J Cardiovasc Med (Hagerstown). 2016 Apr;17(4):263-9. (PMID: 26090917) Rheumatology (Oxford). 2017 Dec 1;56(12):2102-2108. (PMID: 28968868) JAMA. 2016 Nov 8;316(18):1906-1912. (PMID: 27825009) Nat Rev Immunol. 2012 Jul 25;12(8):570-80. (PMID: 22828911) Eur J Rheumatol. 2017 Mar;4(1):66-67. (PMID: 28293457) Heart. 2020 Jul;106(14):1046-1051. (PMID: 32238419) Ann Rheum Dis. 2016 May;75(5):795-810. (PMID: 26888948) Clin Rev Allergy Immunol. 2012 Feb;42(1):102-11. (PMID: 22095454) N Engl J Med. 2021 Jan 7;384(1):31-41. (PMID: 33200890) Cardiol Young. 2019 Apr;29(4):549-551. (PMID: 30931868) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Rheumatology (Oxford). 2018 Aug 1;57(8):1494-1495. (PMID: 30060102) Int J Mol Sci. 2019 Apr 17;20(8):. (PMID: 30999610) J Pediatr. 2014 Jun;164(6):1425-31.e1. (PMID: 24630353) Nature. 1985 Jun 20-26;315(6021):641-7. (PMID: 2989698) Ann Intern Med. 2011 Oct 4;155(7):409-14. (PMID: 21873705) Heart. 2020 Nov 23;:. (PMID: 33229362) J Am Coll Cardiol. 2017 Jun 6;69(22):2775. (PMID: 28571649) J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):217-30. (PMID: 19262208) Nat Rev Drug Discov. 2012 Aug;11(8):633-52. (PMID: 22850787) J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):625-629. (PMID: 32658005) J Exp Med. 2000 Jan 17;191(2):313-20. (PMID: 10637275) J Leukoc Biol. 2010 Mar;87(3):385-95. (PMID: 20015961) J Cardiovasc Pharmacol. 2010 Feb;55(2):117-22. (PMID: 19920765) Circulation. 2017 Sep 12;136(11):996-1006. (PMID: 28663234) Curr Cardiol Rep. 2020 Jun 19;22(8):59. (PMID: 32562029) Cell. 2010 Mar 19;140(6):784-90. (PMID: 20303869) N Engl J Med. 2021 Apr 15;384(15):1475-1476. (PMID: 33852791) Am J Cardiol. 2021 Feb 15;141:113-119. (PMID: 33220316) Int J Cardiol. 2009 Aug 21;136(3):289-93. (PMID: 18674829) J Cardiovasc Med (Hagerstown). 2016 Apr;17(4):256-62. (PMID: 26090915) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Eur J Prev Cardiol. 2020 Jun;27(9):956-964. (PMID: 31610707) Intern Emerg Med. 2018 Jun;13(4):475-489. (PMID: 29633070) Int J Cardiol. 2011 Mar 17;147(3):477-8. (PMID: 21296434) |
| فهرسة مساهمة: | Keywords: interleukin‐1 inhibitors; pericardial disease; pericarditis; recurrent pericarditis |
| المشرفين على المادة: | 0 (Interleukin 1 Receptor Antagonist Protein) 0 (Interleukin Inhibitors) 0 (Interleukin-1) |
| تواريخ الأحداث: | Date Created: 20210927 Date Completed: 20220118 Latest Revision: 20220322 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8649126 |
| DOI: | 10.1161/JAHA.121.021685 |
| PMID: | 34569270 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!